SwitzerlandSwitzerland

Novartis secures share in US6.8bn market for hepatitis C inhibitors

22.02.2012

Basel/Watertown – Swiss Novartis AG has bought a global exclusive licence from Enanta Pharmaceutical Inc. to commercialise drug candidates that help fight off the hepatitis C virus (HCV), which affects 170 million people worldwide. Under the terms of the agreement, Enanta will advance its lead candidate NS5A into clinical development. The firm, which has already gotten IND approval for its HCV replication blocker, will receive an upfront payment of US$34m and milestones that could sum up to US$406m in case of full commercialisation as well as double-digit royalties on global sales. Its picomolar NS5A blocker is a follower to Bristol MyersSquibb’s Phase I first-in-class molecule BMS790052, which seems to address a patient group that is complementary to that of the current standard of care Peg-interferon plus ribavirin. According to experts, NS5A blockers cannot completely replace standard treatment because they are not able to fully eradicate the virus resulting in rapid development of drug resistance. However, they seem to have the potential to broaden the patient group that can benefit from a combination therapy of NS5A blockers plus Peg-interferon and ribavirin. The current standard of care clears most infections with HCV genotype 2 and 3 but succeeds in less than 50% of the patients with genotype 1. According to analyses from Research & Markets the HCV market is to grow annually by about 10% and will reach US$8.6bn in sales in 2016.

SwitzerlandSwitzerland

18.08.2011

Basel – Swiss pharma and diagnostics major Roche AG has agreed to buy privately-held Heidelberg-based mtm laboratories AG, a specialist for kits detecting pre-stages of cervical cancer, for up to EUR190m. Under the terms of the...

SwitzerlandSwitzerland

16.08.2011

Reinach – Evolva SA has got its hands on up to €30m of fresh capital. The Swiss specialist for synthetic biology announced that it has entered into a Standby Equity Distribution Agreement (SEDA) with YA Global Master SPV Ltd. (YA...

SwitzerlandSwitzerland

15.08.2011

Basel/Waltham - Expecting to be bought by Novartis, U.S. biopharmaceutical firm Proteon Therapeutics Inc. has delivered a new $15.2 million financing. The Swiss pharmaceutical company Novartis obtained exclusive option to acquire...

SwitzerlandSwitzerland

03.08.2011

Zurich - Most of the European men share the DNA of the well known Egyptian pharaoh, Tutankhamun, also called the boy King Tut. According to geneticists at Zurich-based genealogy firm iGENEA, up to 70 percent of British men and...

SwitzerlandSwitzerland

13.07.2011

A big financier of biotech deals could be back on track soon. Novartis is interested in further acquisitions, CEO Joe Jimenez said in an interview published by the "Aargauer Zeitung", a Switzerland- based newspaper.The drugmaker...

SwitzerlandSwitzerland

11.06.2011

Basel – Swiss crop group Syngenta plans to construct a new biotech research facility adjacent to its existing research campus at the Research Triangle Park in North Carolina (US). The US$71m investment is scheduled to begin in...

SwitzerlandSwitzerland

10.06.2011

Zurich – Overexpression of two microRNAs trigger development of insulin resistance, a hallmark of type II diabetes which affects about 20% of the elderly (aged 55-74) in the western world. In Nature, a research team headed by...

Displaying results 31 to 40 out of 276

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/3/article/novartis-secures-share-in-us68bn-market-for-hepatitis-c-inhibitors.html

Stock list

All quotes

TOP

  • FLAMEL TECHNOLOGIES (F)14.70 USD11.28%
  • SERODUS (N)3.05 NOK7.02%
  • ADDEX (CH)4.54 CHF5.83%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.48 EUR-10.04%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.43 EUR102.0%

FLOP

  • THROMBOGENICS (B)8.67 EUR-51.3%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.67 EUR-73.1%

No liability assumed, Date: 11.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events